UBS Group’s Imperva, Inc. IMPV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-638,020
| Closed | -$35.5M | – | 8601 |
|
|
2018
Q4 | $35.5M | Buy |
638,020
+562,024
| +740% | +$30.5M | 0.02% | 766 |
|
|
2018
Q3 | $3.53M | Buy |
75,996
+66,682
| +716% | +$3.23M | ﹤0.01% | 2679 |
|
|
2018
Q2 | $450K | Sell |
9,314
-31,937
| -77% | -$1.53M | ﹤0.01% | 4393 |
|
|
2018
Q1 | $1.79M | Buy |
41,251
+38,498
| +1,398% | +$1.73M | ﹤0.01% | 3238 |
|
|
2017
Q4 | $110K | Buy |
2,753
+588
| +27% | +$24.5K | ﹤0.01% | 5288 |
|
|
2017
Q3 | $94K | Sell |
2,165
-24,331
| -92% | -$1.11M | ﹤0.01% | 5359 |
|
|
2017
Q2 | $1.27M | Buy |
26,496
+14,847
| +127% | +$692K | ﹤0.01% | 3402 |
|
|
2017
Q1 | $479K | Buy |
11,649
+8,041
| +223% | +$336K | ﹤0.01% | 4073 |
|
|
2016
Q4 | $139K | Buy |
3,608
+1,017
| +39% | +$41.3K | ﹤0.01% | 5057 |
|
|
2016
Q3 | $139K | Sell |
2,591
-1,166
| -31% | -$54.1K | ﹤0.01% | 4786 |
|
|
2016
Q2 | $162K | Sell |
3,757
-410
| -10% | -$17.2K | ﹤0.01% | 4684 |
|
|
2016
Q1 | $210K | Sell |
4,167
-2,501
| -38% | -$120K | ﹤0.01% | 4460 |
|
|
2015
Q4 | $422K | Buy |
6,668
+2,172
| +48% | +$148K | ﹤0.01% | 4088 |
|
|
2015
Q3 | $295K | Buy |
4,496
+1,737
| +63% | +$115K | ﹤0.01% | 4324 |
|
|
2015
Q2 | $186K | Sell |
2,759
-15,241
| -85% | -$841K | ﹤0.01% | 4932 |
|
|
2015
Q1 | $768K | Buy |
18,000
+1,528
| +9% | +$67.9K | ﹤0.01% | 3801 |
|
|
2014
Q4 | $815K | Buy |
+16,472
| New | +$659K | ﹤0.01% | 3738 |
|
UBS Group's IMPV Position: Q1 2019 in Review
UBS Group sold out of Imperva, Inc. (IMPV) in Q1 2019, closing a stake of 638,020 shares — an estimated $35.5M sold.
UBS Group first reported a position in IMPV in Q4 2014 and held it in 17 quarters. The position peaked at $35.5M in Q4 2018. 0 funds tracked by Wall St. Rank hold IMPV as of Q1 2019.
- UBS Group reported no remaining Imperva, Inc. position as of Q1 2019 after selling out during the quarter.
- UBS Group sold 638,020 Imperva, Inc. shares in Q1 2019, an estimated $35.5M.
- UBS Group first reported a position in Imperva, Inc. in Q4 2014 and held it in 17 quarters.
- UBS Group's Imperva, Inc. position peaked at $35.5M in Q4 2018.
- 0 funds tracked by Wall St. Rank held Imperva, Inc. as of Q1 2019.
Based on UBS Group's 13F filing for Q1 2019, filed 14 May 2019.